Topic Sanofi-aventis

News Sanofi-aventis

• Sanofi Canada invests in prostate cancer research
  

  Sanofi Canada is supporting a five-year study on radiation therapy and prostate cancer. Dr. Tamim Niazi of the Quebec Radiation Oncology GU Group and the JGH is the lead researcher. Sanofi Canada President and CEO, Hugh O'Neill and members of Sanofi's Oncology Team celebrate the collaboration. more

• UCSF, Sanofi collaborate to find new diabetes cures

  The University of California, San Francisco (UCSF) has signed an alliance with Sanofi to share expertise in diabetes research and identify drug targets that could lead to new therapies for both type 1 and type 2 diabetes. The $3.1 million collaboration will bring together scientists in three UCSF la more

• Sanofi licenses worldwide rights on regenerative treatment for osteoarthritis and cartilage disorders from Scil Technology

  Scil Technology GmbH announced that Sanofi has exclusively licensed Scil Technology’s program for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, SCIL Technology will receive an upfront payment and potential milestone payments totaling up to EUR 180 million more

White papers Sanofi-aventis

• Wyeth 'learns and confirms' in India
  

  Aparna Singh (AS), Program Manager with Frost & Sullivan's Chemical Materials and Foods team caught up with Dr. Michael Kolb (Dr. MK) at Frost & Sullivan's Opportunities in Lifescience Molecules: Global Partnership Summit 2006. This annual summit was held at Goa (India) from 21st -23rd May, 2006. more

Publications Sanofi-aventis

• Protected Graft Copolymer (PGC) Basal Formulation of Insulin as Potentially Safer Alternative to Lantus® (Insulin-Glargine): A Streptozotocin-Induced, Diabetic Sprague Dawley R ...

  Purpose To develop a long-acting formulation of native human insulin with a similar pharmacodynamics (PD) profile as the insulin analogue insulin glargine (Lantus®, Sanofi-Aventis) with the expectation of retaining native human insulin’s superior safety profile as insulin glargine is able to activat more

• Sanofi-aventis snaps up microRNA maker

  Sanofi-aventis snaps up microRNA maker Nature Biotechnology 28, 880 (2010). doi:10.1038/nbt0910-880 Author: Nuala Moran more

• Cardiovascular drugs: A determinant of clopidogrel efficacy

  Cardiovascular drugs: A determinant of clopidogrel efficacy Nature Reviews Drug Discovery 10, 100 (2011). doi:10.1038/nrd3377 Author: Charlotte Harrison The antiplatelet drug clopidogrel (Plavix; Sanofi-Aventis/Bristol-Myers Squibb) — which is a purinergic P2Y12 receptor antagonist — is wi more

Market studies Sanofi-aventis

• Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Post-Traumatic Stress Disorder more

• Stem Cell Technologies: World Market Outlook 2011-2021

  How will the stem cells market develop this decade? Our new report shows you that emerging industry and market's revenue potential from 2011 to 2021. This report covers stem cells in therapeutic applications: technologies, products and services. You will assess events, opportunities and activities more

• Acute Coronary Syndrome (ACS) Drug Market Prospects 2011-2021

  What are the commercial prospects for the pharmacological treatment of acute coronary syndrome? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in that industry and market. Our report gives you revenue forecasts to 2021 for treat more

Websites Sanofi-aventis